nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Erlotinib—lung cancer	0.25	0.324	CbGbCtD
Rifaximin—NR1I2—Paclitaxel—lung cancer	0.228	0.296	CbGbCtD
Rifaximin—NR1I2—Docetaxel—lung cancer	0.165	0.214	CbGbCtD
Rifaximin—CYP3A4—Topotecan—lung cancer	0.0181	0.0235	CbGbCtD
Rifaximin—CYP3A4—Gefitinib—lung cancer	0.0165	0.0215	CbGbCtD
Rifaximin—CYP3A4—Teniposide—lung cancer	0.016	0.0208	CbGbCtD
Rifaximin—CYP3A4—Vinorelbine—lung cancer	0.0127	0.0165	CbGbCtD
Rifaximin—CYP3A4—Crizotinib—lung cancer	0.0101	0.0132	CbGbCtD
Rifaximin—CYP3A4—Erlotinib—lung cancer	0.00978	0.0127	CbGbCtD
Rifaximin—CYP3A4—Paclitaxel—lung cancer	0.00896	0.0116	CbGbCtD
Rifaximin—CYP3A4—Irinotecan—lung cancer	0.00883	0.0115	CbGbCtD
Rifaximin—CYP3A4—Vinblastine—lung cancer	0.00785	0.0102	CbGbCtD
Rifaximin—CYP3A4—Etoposide—lung cancer	0.00708	0.00918	CbGbCtD
Rifaximin—CYP3A4—Docetaxel—lung cancer	0.00647	0.0084	CbGbCtD
Rifaximin—CYP3A4—Doxorubicin—lung cancer	0.00483	0.00626	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCC3—lung cancer	0.00341	0.104	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	0.00196	0.0599	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.00179	0.0548	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	0.00174	0.0531	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—RARB—lung cancer	0.00164	0.0501	CbGpPWpGaD
Rifaximin—Rifampicin—ABCC3—lung cancer	0.00154	0.334	CrCbGaD
Rifaximin—CYP3A4—Felbamate Metabolism—CYP2E1—lung cancer	0.00143	0.0436	CbGpPWpGaD
Rifaximin—Rifampicin—UGT1A1—lung cancer	0.00133	0.289	CrCbGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—RARB—lung cancer	0.0013	0.0396	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.00128	0.039	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000997	0.0305	CbGpPWpGaD
Rifaximin—Rifampicin—CYP2A6—lung cancer	0.000838	0.181	CrCbGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCC3—lung cancer	0.000722	0.022	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—lung cancer	0.000678	0.0207	CbGpPWpGaD
Rifaximin—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—lung cancer	0.000636	0.0194	CbGpPWpGaD
Rifaximin—Rifampicin—CYP2E1—lung cancer	0.000595	0.129	CrCbGaD
Rifaximin—CYP3A4—Xenobiotics—CYP2A7—lung cancer	0.000457	0.014	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—UGT1A1—lung cancer	0.000434	0.0132	CbGpPWpGaD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—lung cancer	0.000397	0.0121	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—lung cancer	0.000395	0.0121	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—GSTA1—lung cancer	0.000381	0.0117	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—ABCG2—lung cancer	0.000376	0.0115	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—lung cancer	0.000367	0.0112	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—UGT1A1—lung cancer	0.000355	0.0108	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—lung cancer	0.000318	0.0097	CbGpPWpGaD
Rifaximin—Rifampicin—ABCB1—lung cancer	0.000312	0.0675	CrCbGaD
Rifaximin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—lung cancer	0.000307	0.00939	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—HSD17B10—lung cancer	0.000297	0.00908	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—SKI—lung cancer	0.000279	0.00852	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—lung cancer	0.00027	0.00825	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP2A6—lung cancer	0.000266	0.00812	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP2A6—lung cancer	0.000256	0.00781	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—lung cancer	0.000249	0.00762	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—NQO1—lung cancer	0.000243	0.00743	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EIF2B4—lung cancer	0.000241	0.00737	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—lung cancer	0.000238	0.00727	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	0.000227	0.00693	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP2E1—lung cancer	0.000226	0.0069	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—RARB—lung cancer	0.000224	0.00684	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—lung cancer	0.000224	0.00684	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NPPA—lung cancer	0.000218	0.00667	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP2E1—lung cancer	0.000217	0.00664	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HNRNPA2B1—lung cancer	0.000215	0.00657	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.000207	0.00634	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	0.000201	0.00614	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—KHSRP—lung cancer	0.000197	0.00601	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000194	0.00593	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.00019	0.0058	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.000187	0.00573	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—GSTM1—lung cancer	0.000186	0.00569	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	0.000182	0.00557	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—CYP1A1—lung cancer	0.000177	0.0054	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EIF2B5—lung cancer	0.000172	0.00525	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—APC—lung cancer	0.000169	0.00517	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NOTCH3—lung cancer	0.000165	0.00505	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP1A1—lung cancer	0.000162	0.00496	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—JUNB—lung cancer	0.000157	0.00478	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP1A1—lung cancer	0.000156	0.00477	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DICER1—lung cancer	0.000156	0.00475	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.000154	0.0047	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.000148	0.00451	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SKI—lung cancer	0.000134	0.0041	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000121	0.0037	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	0.000116	0.00355	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000115	0.00352	CbGpPWpGaD
Rifaximin—Infestation—Methotrexate—lung cancer	0.000112	0.000585	CcSEcCtD
Rifaximin—Depression—Methotrexate—lung cancer	0.000112	0.000583	CcSEcCtD
Rifaximin—Anorexia—Paclitaxel—lung cancer	0.000112	0.000582	CcSEcCtD
Rifaximin—Hypotension—Etoposide—lung cancer	0.000112	0.000582	CcSEcCtD
Rifaximin—Pain—Cisplatin—lung cancer	0.000112	0.000581	CcSEcCtD
Rifaximin—Vomiting—Vinorelbine—lung cancer	0.000111	0.000577	CcSEcCtD
Rifaximin—Body temperature increased—Gemcitabine—lung cancer	0.000111	0.000577	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.00011	0.00337	CbGpPWpGaD
Rifaximin—Rash—Vinorelbine—lung cancer	0.00011	0.000572	CcSEcCtD
Rifaximin—Dermatitis—Vinorelbine—lung cancer	0.00011	0.000572	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—lung cancer	0.00011	0.000572	CcSEcCtD
Rifaximin—Hypotension—Paclitaxel—lung cancer	0.00011	0.000571	CcSEcCtD
Rifaximin—Headache—Vinorelbine—lung cancer	0.000109	0.000569	CcSEcCtD
Rifaximin—Syncope—Docetaxel—lung cancer	0.000109	0.000569	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—lung cancer	0.000109	0.000568	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000109	0.00333	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RARB—lung cancer	0.000108	0.00329	CbGpPWpGaD
Rifaximin—Feeling abnormal—Cisplatin—lung cancer	0.000108	0.00056	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—lung cancer	0.000107	0.000558	CcSEcCtD
Rifaximin—Loss of consciousness—Docetaxel—lung cancer	0.000107	0.000557	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000107	0.000556	CcSEcCtD
Rifaximin—Dyspnoea—Etoposide—lung cancer	0.000107	0.000555	CcSEcCtD
Rifaximin—Cough—Docetaxel—lung cancer	0.000106	0.000553	CcSEcCtD
Rifaximin—Insomnia—Paclitaxel—lung cancer	0.000106	0.000552	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—lung cancer	0.000106	0.000552	CcSEcCtD
Rifaximin—Hypersensitivity—Irinotecan—lung cancer	0.000106	0.000552	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NPPA—lung cancer	0.000105	0.00321	CbGpPWpGaD
Rifaximin—Dyspnoea—Paclitaxel—lung cancer	0.000105	0.000544	CcSEcCtD
Rifaximin—Decreased appetite—Etoposide—lung cancer	0.000104	0.000541	CcSEcCtD
Rifaximin—Arthralgia—Docetaxel—lung cancer	0.000104	0.00054	CcSEcCtD
Rifaximin—Myalgia—Docetaxel—lung cancer	0.000104	0.00054	CcSEcCtD
Rifaximin—Chest pain—Docetaxel—lung cancer	0.000104	0.00054	CcSEcCtD
Rifaximin—Nausea—Vinorelbine—lung cancer	0.000104	0.000539	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Etoposide—lung cancer	0.000103	0.000538	CcSEcCtD
Rifaximin—Body temperature increased—Cisplatin—lung cancer	0.000103	0.000537	CcSEcCtD
Rifaximin—Asthenia—Irinotecan—lung cancer	0.000103	0.000537	CcSEcCtD
Rifaximin—Fatigue—Etoposide—lung cancer	0.000103	0.000537	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000103	0.000536	CcSEcCtD
Rifaximin—Pain—Etoposide—lung cancer	0.000102	0.000533	CcSEcCtD
Rifaximin—Constipation—Etoposide—lung cancer	0.000102	0.000533	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—lung cancer	0.000102	0.000531	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—lung cancer	0.000102	0.000531	CcSEcCtD
Rifaximin—Decreased appetite—Paclitaxel—lung cancer	0.000102	0.000531	CcSEcCtD
Rifaximin—Dry mouth—Docetaxel—lung cancer	0.000101	0.000528	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000101	0.000528	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—lung cancer	0.000101	0.000528	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000101	0.000527	CcSEcCtD
Rifaximin—Fatigue—Paclitaxel—lung cancer	0.000101	0.000527	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—lung cancer	0.000101	0.000525	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—lung cancer	0.000101	0.000525	CcSEcCtD
Rifaximin—Asthenia—Gemcitabine—lung cancer	0.0001	0.000523	CcSEcCtD
Rifaximin—Constipation—Paclitaxel—lung cancer	0.0001	0.000522	CcSEcCtD
Rifaximin—Pain—Paclitaxel—lung cancer	0.0001	0.000522	CcSEcCtD
Rifaximin—Confusional state—Docetaxel—lung cancer	0.0001	0.000522	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—lung cancer	0.0001	0.000521	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—lung cancer	9.95e-05	0.000519	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—lung cancer	9.95e-05	0.000519	CcSEcCtD
Rifaximin—Anaphylactic shock—Docetaxel—lung cancer	9.94e-05	0.000518	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—lung cancer	9.92e-05	0.000517	CcSEcCtD
Rifaximin—Pruritus—Gemcitabine—lung cancer	9.91e-05	0.000516	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—lung cancer	9.88e-05	0.000515	CcSEcCtD
Rifaximin—Infection—Docetaxel—lung cancer	9.87e-05	0.000514	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—lung cancer	9.86e-05	0.000514	CcSEcCtD
Rifaximin—Feeling abnormal—Etoposide—lung cancer	9.85e-05	0.000513	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—lung cancer	9.84e-05	0.000512	CcSEcCtD
Rifaximin—Diarrhoea—Irinotecan—lung cancer	9.83e-05	0.000512	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—lung cancer	9.78e-05	0.000509	CcSEcCtD
Rifaximin—Gastrointestinal pain—Etoposide—lung cancer	9.78e-05	0.000509	CcSEcCtD
Rifaximin—Shock—Docetaxel—lung cancer	9.77e-05	0.000509	CcSEcCtD
Rifaximin—Nervous system disorder—Docetaxel—lung cancer	9.74e-05	0.000508	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—lung cancer	9.72e-05	0.000507	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—lung cancer	9.72e-05	0.000507	CcSEcCtD
Rifaximin—Feeling abnormal—Paclitaxel—lung cancer	9.66e-05	0.000503	CcSEcCtD
Rifaximin—Skin disorder—Docetaxel—lung cancer	9.65e-05	0.000503	CcSEcCtD
Rifaximin—Hypersensitivity—Cisplatin—lung cancer	9.61e-05	0.000501	CcSEcCtD
Rifaximin—Gastrointestinal pain—Paclitaxel—lung cancer	9.58e-05	0.000499	CcSEcCtD
Rifaximin—Diarrhoea—Gemcitabine—lung cancer	9.58e-05	0.000499	CcSEcCtD
Rifaximin—Dizziness—Irinotecan—lung cancer	9.5e-05	0.000495	CcSEcCtD
Rifaximin—Urticaria—Etoposide—lung cancer	9.5e-05	0.000495	CcSEcCtD
Rifaximin—Anorexia—Docetaxel—lung cancer	9.47e-05	0.000493	CcSEcCtD
Rifaximin—Abdominal pain—Etoposide—lung cancer	9.45e-05	0.000492	CcSEcCtD
Rifaximin—Body temperature increased—Etoposide—lung cancer	9.45e-05	0.000492	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—lung cancer	9.4e-05	0.00049	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	9.38e-05	0.00287	CbGpPWpGaD
Rifaximin—Asthenia—Cisplatin—lung cancer	9.36e-05	0.000488	CcSEcCtD
Rifaximin—Urticaria—Paclitaxel—lung cancer	9.31e-05	0.000485	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CAT—lung cancer	9.31e-05	0.00284	CbGpPWpGaD
Rifaximin—Hypotension—Docetaxel—lung cancer	9.28e-05	0.000484	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—lung cancer	9.27e-05	0.000483	CcSEcCtD
Rifaximin—Abdominal pain—Paclitaxel—lung cancer	9.27e-05	0.000483	CcSEcCtD
Rifaximin—Body temperature increased—Paclitaxel—lung cancer	9.27e-05	0.000483	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	9.26e-05	0.00283	CbGpPWpGaD
Rifaximin—Epistaxis—Doxorubicin—lung cancer	9.17e-05	0.000478	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—lung cancer	9.14e-05	0.000476	CcSEcCtD
Rifaximin—Vomiting—Irinotecan—lung cancer	9.14e-05	0.000476	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—lung cancer	9.08e-05	0.000473	CcSEcCtD
Rifaximin—Rash—Irinotecan—lung cancer	9.06e-05	0.000472	CcSEcCtD
Rifaximin—Dermatitis—Irinotecan—lung cancer	9.05e-05	0.000472	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Docetaxel—lung cancer	9.05e-05	0.000472	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CNDP2—lung cancer	9.04e-05	0.00276	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM2—lung cancer	9.04e-05	0.00276	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HSPB1—lung cancer	9.03e-05	0.00276	CbGpPWpGaD
Rifaximin—Headache—Irinotecan—lung cancer	9e-05	0.000469	CcSEcCtD
Rifaximin—Insomnia—Docetaxel—lung cancer	8.99e-05	0.000468	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	8.94e-05	0.00273	CbGpPWpGaD
Rifaximin—Diarrhoea—Cisplatin—lung cancer	8.93e-05	0.000465	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	8.92e-05	0.00273	CbGpPWpGaD
Rifaximin—Vomiting—Gemcitabine—lung cancer	8.9e-05	0.000464	CcSEcCtD
Rifaximin—Dyspnoea—Docetaxel—lung cancer	8.86e-05	0.000461	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—lung cancer	8.83e-05	0.00046	CcSEcCtD
Rifaximin—Rash—Gemcitabine—lung cancer	8.83e-05	0.00046	CcSEcCtD
Rifaximin—Dermatitis—Gemcitabine—lung cancer	8.82e-05	0.000459	CcSEcCtD
Rifaximin—Hypersensitivity—Etoposide—lung cancer	8.81e-05	0.000459	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—lung cancer	8.77e-05	0.000457	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—lung cancer	8.77e-05	0.000457	CcSEcCtD
Rifaximin—Headache—Gemcitabine—lung cancer	8.77e-05	0.000457	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—lung cancer	8.75e-05	0.000456	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—lung cancer	8.73e-05	0.000455	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—lung cancer	8.68e-05	0.000452	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—lung cancer	8.66e-05	0.000451	CcSEcCtD
Rifaximin—Decreased appetite—Docetaxel—lung cancer	8.64e-05	0.00045	CcSEcCtD
Rifaximin—Hypersensitivity—Paclitaxel—lung cancer	8.64e-05	0.00045	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—lung cancer	8.62e-05	0.000449	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—lung cancer	8.6e-05	0.000448	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Docetaxel—lung cancer	8.58e-05	0.000447	CcSEcCtD
Rifaximin—Asthenia—Etoposide—lung cancer	8.58e-05	0.000447	CcSEcCtD
Rifaximin—Fatigue—Docetaxel—lung cancer	8.57e-05	0.000446	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—lung cancer	8.56e-05	0.000446	CcSEcCtD
Rifaximin—Nausea—Irinotecan—lung cancer	8.54e-05	0.000445	CcSEcCtD
Rifaximin—Constipation—Docetaxel—lung cancer	8.5e-05	0.000443	CcSEcCtD
Rifaximin—Pain—Docetaxel—lung cancer	8.5e-05	0.000443	CcSEcCtD
Rifaximin—Back pain—Methotrexate—lung cancer	8.49e-05	0.000442	CcSEcCtD
Rifaximin—Pruritus—Etoposide—lung cancer	8.46e-05	0.000441	CcSEcCtD
Rifaximin—Asthenia—Paclitaxel—lung cancer	8.41e-05	0.000438	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	8.34e-05	0.00255	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—CREBBP—lung cancer	8.32e-05	0.00254	CbGpPWpGaD
Rifaximin—Nausea—Gemcitabine—lung cancer	8.32e-05	0.000433	CcSEcCtD
Rifaximin—Vomiting—Cisplatin—lung cancer	8.3e-05	0.000432	CcSEcCtD
Rifaximin—Pruritus—Paclitaxel—lung cancer	8.29e-05	0.000432	CcSEcCtD
Rifaximin—Rash—Cisplatin—lung cancer	8.23e-05	0.000429	CcSEcCtD
Rifaximin—Dermatitis—Cisplatin—lung cancer	8.22e-05	0.000428	CcSEcCtD
Rifaximin—Feeling abnormal—Docetaxel—lung cancer	8.19e-05	0.000427	CcSEcCtD
Rifaximin—Diarrhoea—Etoposide—lung cancer	8.18e-05	0.000426	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP2A7—lung cancer	8.18e-05	0.0025	CbGpPWpGaD
Rifaximin—Ill-defined disorder—Methotrexate—lung cancer	8.14e-05	0.000424	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—lung cancer	8.14e-05	0.000424	CcSEcCtD
Rifaximin—Gastrointestinal pain—Docetaxel—lung cancer	8.12e-05	0.000423	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—lung cancer	8.11e-05	0.000423	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—lung cancer	8.1e-05	0.000422	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	8.07e-05	0.00246	CbGpPWpGaD
Rifaximin—Diarrhoea—Paclitaxel—lung cancer	8.02e-05	0.000418	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NOTCH3—lung cancer	7.96e-05	0.00243	CbGpPWpGaD
Rifaximin—Angiopathy—Doxorubicin—lung cancer	7.92e-05	0.000413	CcSEcCtD
Rifaximin—Malaise—Methotrexate—lung cancer	7.91e-05	0.000412	CcSEcCtD
Rifaximin—Dizziness—Etoposide—lung cancer	7.91e-05	0.000412	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—lung cancer	7.88e-05	0.000411	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—lung cancer	7.87e-05	0.00041	CcSEcCtD
Rifaximin—Abdominal pain—Docetaxel—lung cancer	7.85e-05	0.000409	CcSEcCtD
Rifaximin—Body temperature increased—Docetaxel—lung cancer	7.85e-05	0.000409	CcSEcCtD
Rifaximin—Dizziness—Paclitaxel—lung cancer	7.75e-05	0.000404	CcSEcCtD
Rifaximin—Nausea—Cisplatin—lung cancer	7.75e-05	0.000404	CcSEcCtD
Rifaximin—Cough—Methotrexate—lung cancer	7.66e-05	0.000399	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—lung cancer	7.65e-05	0.000398	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	7.6e-05	0.00232	CbGpPWpGaD
Rifaximin—Vomiting—Etoposide—lung cancer	7.6e-05	0.000396	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—lung cancer	7.6e-05	0.000396	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—JUNB—lung cancer	7.54e-05	0.0023	CbGpPWpGaD
Rifaximin—Rash—Etoposide—lung cancer	7.54e-05	0.000393	CcSEcCtD
Rifaximin—Dermatitis—Etoposide—lung cancer	7.53e-05	0.000392	CcSEcCtD
Rifaximin—Headache—Etoposide—lung cancer	7.49e-05	0.00039	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—lung cancer	7.49e-05	0.00039	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—lung cancer	7.47e-05	0.000389	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—lung cancer	7.47e-05	0.000389	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—lung cancer	7.47e-05	0.000389	CcSEcCtD
Rifaximin—Vomiting—Paclitaxel—lung cancer	7.45e-05	0.000388	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.42e-05	0.000386	CcSEcCtD
Rifaximin—Rash—Paclitaxel—lung cancer	7.39e-05	0.000385	CcSEcCtD
Rifaximin—Dermatitis—Paclitaxel—lung cancer	7.38e-05	0.000385	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—lung cancer	7.38e-05	0.000385	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—lung cancer	7.35e-05	0.000383	CcSEcCtD
Rifaximin—Headache—Paclitaxel—lung cancer	7.34e-05	0.000383	CcSEcCtD
Rifaximin—Hypersensitivity—Docetaxel—lung cancer	7.32e-05	0.000381	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—lung cancer	7.3e-05	0.000381	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA3—lung cancer	7.29e-05	0.00223	CbGpPWpGaD
Rifaximin—Confusional state—Methotrexate—lung cancer	7.22e-05	0.000376	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	7.19e-05	0.0022	CbGpPWpGaD
Rifaximin—Anaphylactic shock—Methotrexate—lung cancer	7.16e-05	0.000373	CcSEcCtD
Rifaximin—Asthenia—Docetaxel—lung cancer	7.13e-05	0.000371	CcSEcCtD
Rifaximin—Infection—Methotrexate—lung cancer	7.11e-05	0.000371	CcSEcCtD
Rifaximin—Nausea—Etoposide—lung cancer	7.1e-05	0.00037	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—lung cancer	7.05e-05	0.000367	CcSEcCtD
Rifaximin—Pruritus—Docetaxel—lung cancer	7.03e-05	0.000366	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—lung cancer	7.02e-05	0.000366	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—lung cancer	7.02e-05	0.000366	CcSEcCtD
Rifaximin—Nausea—Paclitaxel—lung cancer	6.96e-05	0.000363	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—lung cancer	6.96e-05	0.000362	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—lung cancer	6.92e-05	0.000361	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—lung cancer	6.85e-05	0.000357	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—lung cancer	6.83e-05	0.000356	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—lung cancer	6.83e-05	0.000356	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—lung cancer	6.81e-05	0.000355	CcSEcCtD
Rifaximin—Diarrhoea—Docetaxel—lung cancer	6.8e-05	0.000354	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	6.74e-05	0.00206	CbGpPWpGaD
Rifaximin—Hypotension—Methotrexate—lung cancer	6.69e-05	0.000349	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—lung cancer	6.68e-05	0.000348	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA4—lung cancer	6.67e-05	0.00204	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	6.65e-05	0.00203	CbGpPWpGaD
Rifaximin—Cough—Doxorubicin—lung cancer	6.63e-05	0.000345	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	6.58e-05	0.00201	CbGpPWpGaD
Rifaximin—Dizziness—Docetaxel—lung cancer	6.57e-05	0.000342	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—lung cancer	6.52e-05	0.00034	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA2—lung cancer	6.5e-05	0.00199	CbGpPWpGaD
Rifaximin—Insomnia—Methotrexate—lung cancer	6.48e-05	0.000337	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—lung cancer	6.47e-05	0.000337	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—lung cancer	6.47e-05	0.000337	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—lung cancer	6.47e-05	0.000337	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.42e-05	0.000335	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—lung cancer	6.39e-05	0.000333	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—lung cancer	6.38e-05	0.000333	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—lung cancer	6.33e-05	0.00033	CcSEcCtD
Rifaximin—Vomiting—Docetaxel—lung cancer	6.32e-05	0.000329	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA1—lung cancer	6.27e-05	0.00192	CbGpPWpGaD
Rifaximin—Rash—Docetaxel—lung cancer	6.26e-05	0.000326	CcSEcCtD
Rifaximin—Dermatitis—Docetaxel—lung cancer	6.26e-05	0.000326	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—lung cancer	6.25e-05	0.000326	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—lung cancer	6.22e-05	0.000324	CcSEcCtD
Rifaximin—Headache—Docetaxel—lung cancer	6.22e-05	0.000324	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—lung cancer	6.2e-05	0.000323	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—lung cancer	6.18e-05	0.000322	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—lung cancer	6.17e-05	0.000322	CcSEcCtD
Rifaximin—Infection—Doxorubicin—lung cancer	6.16e-05	0.000321	CcSEcCtD
Rifaximin—Pain—Methotrexate—lung cancer	6.12e-05	0.000319	CcSEcCtD
Rifaximin—Shock—Doxorubicin—lung cancer	6.1e-05	0.000318	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—lung cancer	6.08e-05	0.000317	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—lung cancer	6.02e-05	0.000314	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—lung cancer	5.99e-05	0.000312	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	5.92e-05	0.00181	CbGpPWpGaD
Rifaximin—Anorexia—Doxorubicin—lung cancer	5.91e-05	0.000308	CcSEcCtD
Rifaximin—Nausea—Docetaxel—lung cancer	5.9e-05	0.000307	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—lung cancer	5.9e-05	0.000307	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—lung cancer	5.86e-05	0.000305	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—UGT1A1—lung cancer	5.83e-05	0.00178	CbGpPWpGaD
Rifaximin—Hypotension—Doxorubicin—lung cancer	5.79e-05	0.000302	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	5.75e-05	0.00176	CbGpPWpGaD
Rifaximin—Urticaria—Methotrexate—lung cancer	5.69e-05	0.000296	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—lung cancer	5.66e-05	0.000295	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—lung cancer	5.66e-05	0.000295	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.65e-05	0.000294	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—lung cancer	5.61e-05	0.000292	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—lung cancer	5.53e-05	0.000288	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ERCC2—lung cancer	5.47e-05	0.00167	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	5.46e-05	0.00167	CbGpPWpGaD
Rifaximin—Decreased appetite—Doxorubicin—lung cancer	5.39e-05	0.000281	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—lung cancer	5.35e-05	0.000279	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—lung cancer	5.35e-05	0.000279	CcSEcCtD
Rifaximin—Pain—Doxorubicin—lung cancer	5.3e-05	0.000276	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—lung cancer	5.3e-05	0.000276	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—lung cancer	5.28e-05	0.000275	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	5.14e-05	0.00157	CbGpPWpGaD
Rifaximin—Asthenia—Methotrexate—lung cancer	5.14e-05	0.000268	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—lung cancer	5.11e-05	0.000266	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—lung cancer	5.07e-05	0.000264	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—lung cancer	5.07e-05	0.000264	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	5.02e-05	0.00154	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—HPGDS—lung cancer	4.96e-05	0.00151	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—lung cancer	4.94e-05	0.00151	CbGpPWpGaD
Rifaximin—Urticaria—Doxorubicin—lung cancer	4.93e-05	0.000257	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—lung cancer	4.9e-05	0.000255	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—lung cancer	4.9e-05	0.000255	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—lung cancer	4.9e-05	0.000255	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTT1—lung cancer	4.81e-05	0.00147	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP2A6—lung cancer	4.75e-05	0.00145	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GCLC—lung cancer	4.75e-05	0.00145	CbGpPWpGaD
Rifaximin—Dizziness—Methotrexate—lung cancer	4.74e-05	0.000247	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—lung cancer	4.57e-05	0.000238	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—lung cancer	4.55e-05	0.000237	CcSEcCtD
Rifaximin—Rash—Methotrexate—lung cancer	4.52e-05	0.000235	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—lung cancer	4.51e-05	0.000235	CcSEcCtD
Rifaximin—Headache—Methotrexate—lung cancer	4.49e-05	0.000234	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—lung cancer	4.45e-05	0.000232	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—lung cancer	4.39e-05	0.000229	CcSEcCtD
Rifaximin—Nausea—Methotrexate—lung cancer	4.25e-05	0.000222	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—lung cancer	4.24e-05	0.000221	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—lung cancer	4.1e-05	0.000214	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	4.07e-05	0.00124	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP2E1—lung cancer	4.04e-05	0.00123	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—CREBBP—lung cancer	4.01e-05	0.00122	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	3.98e-05	0.00122	CbGpPWpGaD
Rifaximin—Vomiting—Doxorubicin—lung cancer	3.94e-05	0.000205	CcSEcCtD
Rifaximin—Rash—Doxorubicin—lung cancer	3.91e-05	0.000204	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—lung cancer	3.91e-05	0.000203	CcSEcCtD
Rifaximin—Headache—Doxorubicin—lung cancer	3.88e-05	0.000202	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—lung cancer	3.68e-05	0.000192	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTP1—lung cancer	3.33e-05	0.00102	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	3.29e-05	0.001	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—lung cancer	3.06e-05	0.000935	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	3.02e-05	0.000923	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP1A1—lung cancer	2.9e-05	0.000887	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	2.86e-05	0.000875	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AZIN2—lung cancer	2.55e-05	0.00078	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—COL4A3BP—lung cancer	2.55e-05	0.00078	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MAPK3—lung cancer	2.45e-05	0.000747	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—lung cancer	2.38e-05	0.000727	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ATP5H—lung cancer	2.17e-05	0.000663	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—POMC—lung cancer	2.16e-05	0.000661	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PLBD1—lung cancer	1.93e-05	0.000591	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD17B10—lung cancer	1.77e-05	0.000541	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—lung cancer	1.65e-05	0.000504	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CKB—lung cancer	1.65e-05	0.000503	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CNDP2—lung cancer	1.55e-05	0.000473	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM2—lung cancer	1.55e-05	0.000473	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTMR3—lung cancer	1.5e-05	0.00046	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PGAM1—lung cancer	1.47e-05	0.000448	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2A7—lung cancer	1.4e-05	0.000427	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SDC4—lung cancer	1.37e-05	0.000418	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RRM1—lung cancer	1.25e-05	0.000381	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA3—lung cancer	1.25e-05	0.000381	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—B4GALT5—lung cancer	1.17e-05	0.000358	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA4—lung cancer	1.14e-05	0.000348	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA2—lung cancer	1.11e-05	0.00034	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA1—lung cancer	1.07e-05	0.000328	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCC3—lung cancer	1.06e-05	0.000324	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKR1C1—lung cancer	1.03e-05	0.000314	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UGT1A1—lung cancer	9.97e-06	0.000305	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GNG11—lung cancer	9.61e-06	0.000294	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALDOA—lung cancer	9.15e-06	0.00028	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA3—lung cancer	8.88e-06	0.000271	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG2—lung cancer	8.64e-06	0.000264	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADCY1—lung cancer	8.64e-06	0.000264	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HPGDS—lung cancer	8.47e-06	0.000259	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ENO2—lung cancer	8.47e-06	0.000259	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPP2R1B—lung cancer	8.42e-06	0.000257	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTT1—lung cancer	8.22e-06	0.000251	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GCLC—lung cancer	8.12e-06	0.000248	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2A6—lung cancer	8.12e-06	0.000248	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ENO1—lung cancer	7.7e-06	0.000235	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2E1—lung cancer	6.91e-06	0.000211	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NQO1—lung cancer	6.83e-06	0.000209	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—STK11—lung cancer	6.16e-06	0.000188	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTP1—lung cancer	5.7e-06	0.000174	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CAT—lung cancer	5.54e-06	0.000169	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCB1—lung cancer	5.39e-06	0.000165	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TYMS—lung cancer	5.3e-06	0.000162	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—lung cancer	5.24e-06	0.00016	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1A1—lung cancer	4.96e-06	0.000152	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ERCC2—lung cancer	4.92e-06	0.00015	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA1—lung cancer	4.26e-06	0.00013	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—lung cancer	3.89e-06	0.000119	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—POMC—lung cancer	3.7e-06	0.000113	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CREBBP—lung cancer	3.6e-06	0.00011	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CD—lung cancer	3.42e-06	0.000104	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—lung cancer	3.37e-06	0.000103	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CB—lung cancer	2.98e-06	9.1e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGS2—lung cancer	2.95e-06	9.02e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTEN—lung cancer	2.57e-06	7.86e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—EP300—lung cancer	2.45e-06	7.5e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CA—lung cancer	1.82e-06	5.55e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—lung cancer	1.48e-06	4.53e-05	CbGpPWpGaD
